Selux Diagnostics Secures Additional $48 Million To Fight Superbugs With Innovative Tech

Selux Diagnostics, Inc., a pioneering biotech startup based in Boston, has recently announced a significant financial boost of $48 million to propel the commercialization of its innovative Selux Next Generation Phenotyping (NGP) System across the United States. This cutting-edge technology, designed to combat the rising threat of superbug infections and antimicrobial resistance (AMR), marks a significant leap forward in the field of Antibiotic Susceptibility Testing (AST).

The Selux NGP System stands out for its ability to deliver AST results on the same day, a stark contrast to the current standard which can take between 3-5 days. This rapid turnaround is crucial for personalizing antibiotic therapy more effectively and reducing the dependency on broad-spectrum antibiotics, which are known contributors to the increase in superbug prevalence.

The latest funding round was spearheaded by RA Capital Management and saw contributions from Northpond Ventures, Sands Capital, and Schooner Capital. This financial injection is poised to revolutionize patient care by significantly shortening the time needed to make informed antibiotic choices.

Earlier this year, Selux also achieved its third FDA clearance, setting a new benchmark as the only FDA-cleared, single-platform rapid AST technology capable of delivering results within hours for both isolated colonies and positive blood cultures. This achievement underscores the technological advancements and potential of the Selux NGP System in addressing AMR challenges.

Steve Lufkin, CEO of Selux Diagnostics, expressed gratitude towards their partners and dedicated team for their support in ushering in a new era of personalized diagnostics. The company's mission to accelerate the selection of personalized antimicrobial therapy aligns with global efforts to save lives, reduce hospital stays, and mitigate antibiotic resistance.

The development and commercialization of the Selux NGP System have been supported by federal funds from various U.S. Department of Health and Human Services (HHS) agencies, including the Administration for Strategic Preparedness and Response (ASPR) and the Biomedical Advanced Research and Development Authority (BARDA), under contract number HHSO100201800013C.

Selux Diagnostics is at the forefront of transforming patient care by offering rapid and accurate AST solutions. The Selux NGP System comprises several components including the Positive Blood Culture (PBC) Separator, Selux Inoculator, Selux Analyzer, and panels for both Gram-negative and Gram-positive bacteria. For more details on this revolutionary technology, interested parties are encouraged to visit www.seluxdx.com.